PTJ
KLRS

Paul Tudor Jones’s Kalaris Therapeutics KLRS Stock Holding History

Paul Tudor Jones’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,157
Closed -$20.8K – 3803
2024
Q4 		$20.8K Hold
2,157
– – ﹤0.01% 2938
2024
Q3 		$40.1K Hold
2,157
– – ﹤0.01% 2621
2024
Q2 		$35.9K Hold
2,157
– – ﹤0.01% 2238
2024
Q1 		$37.5K Hold
2,157
– – ﹤0.01% 2123
2023
Q4 		$33.7K Hold
2,157
– – ﹤0.01% 2276
2023
Q3 		$107K Sell
2,157
-1,044
-33% -$71.1K ﹤0.01% 2145
2023
Q2 		$250K Buy
3,201
+2,037
+175% +$194K ﹤0.01% 2102
2023
Q1 		$105K Buy
+1,164
New +$148K ﹤0.01% 2258
2022
Q4 		– Sell
-1,115
Closed -$202K – 2932
2022
Q3 		$202K Sell
1,115
-502
-31% -$78.2K ﹤0.01% 2072
2022
Q2 		$145K Buy
1,617
+569
+54% +$59.7K ﹤0.01% 1879
2022
Q1 		$163K Sell
1,048
-25
-2% -$4.99K ﹤0.01% 1797
2021
Q4 		$319K Buy
+1,073
New +$498K 0.01% 1799
2021
Q3 		– Sell
-1,543
Closed -$700K – 2874
2021
Q2 		$700K Buy
+1,543
New +$797K 0.01% 1018

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's KLRS Position: Q1 2025 in Review

Paul Tudor Jones sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 2,157 shares — an estimated $20.8K sold.

Paul Tudor Jones first reported a position in KLRS in Q2 2021 and held it in 13 quarters. The position peaked at $700K in Q2 2021. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Paul Tudor Jones reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 2,157 Kalaris Therapeutics shares in Q1 2025, an estimated $20.8K.
  • Paul Tudor Jones first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 13 quarters.
  • Paul Tudor Jones's Kalaris Therapeutics position peaked at $700K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Tudor Investment Corp's 13F filing for Q1 2025, filed 15 May 2025.